Sherbrooke Park Advisers LLC Incyte Corp Transaction History

Sherbrooke Park Advisers LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$51.18 - $63.75 $438,663 - $546,401	8,571 Added 53.12%	24,707 $1.5 Billion
Q1 2024 May 15, 2024	BUY	$56.55 - $66.59 $618,430 - $728,228	10,936 Added 210.31%	16,136 $919 Million
Q4 2023 Feb 14, 2024	SELL	$52.16 - $64.19 $1.41 Million - $1.73 Million	-27,023 Reduced 83.86%	5,200 $327 Million
Q3 2023 Nov 14, 2023	BUY	$57.77 - $65.93 $1.16 Million - $1.33 Million	20,123 Added 166.31%	32,223 $1.86 Billion
Q2 2023 Aug 14, 2023	BUY	$60.95 - $75.51 $195,040 - $241,632	3,200 Added 35.96%	12,100 $753 Million
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $625,047 - $765,489	8,900 New	8,900 $643 Million

657

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.5B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Sherbrooke Park Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Sherbrooke Park Advisers LLC with notifications on news.